Top

Published in:

01-02-2003 | Commentary

Akt2: a role in breast cancer metastasis

Authors: Noan-Minh Chau, Margaret Ashcroft

Published in: Breast Cancer Research | Issue 1/2003

Abstract

Metastasis in breast cancer significantly increases morbidity and mortality. The 5-year survival rate reduces from 90% for localised disease to about 20% once metastasis has taken place. The phosphoinositide 3-kinase/Akt signalling pathway has an important role in cell motility, invasion and metastasis. However, the precise contribution of the Akt kinase family members, Akt1, Akt2 and Akt3, in mediating these processes is unclear. The possibility that they have distinct functions in tumour progression is particularly interesting.

Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, Danino M, Karlan BY, Slamon DJ: Overexpression of AKT2/protein kinase B beta leads to up-regulation of β¹ integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res. 2003, 63: 196-206.PubMed

Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN, Testa JR: AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA. 1992, 89: 9267-9271.CrossRefPubMedPubMedCentral

Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR, Tsichlis PN: The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell. 1995, 81: 727-736.CrossRefPubMed

Scheid MP, Woodgett JR: Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett. 2003, 546: 108-112. 10.1016/S0014-5793(03)00562-3.CrossRefPubMed

Nicholson KM, Anderson NG: The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 2002, 14: 381-395. 10.1016/S0898-6568(01)00271-6.CrossRefPubMed

Vivanco I, Sawyers CL: The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat Rev Cancer. 2002, 2: 489-501. 10.1038/nrc839.CrossRefPubMed

Testa JR, Bellacosa A: Akt plays a central role in tumorigenesis. Proc Natl Acad Sci USA. 2001, 98: 10983-10985. 10.1073/pnas.211430998.CrossRefPubMedPubMedCentral

Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV, Cheng JQ: Phosphatidylinositol-3-OH Kinase (PI3-K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor α (ERα) via interaction between ERα and PI3-K. Cancer Res. 2001, 61: 5985-5991.PubMed

Nakatani K, Thompson DA, Barthel A, Sakaue H, Liu W, Weigel RJ, Roth RA: Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem. 1999, 274: 21528-21532. 10.1074/jbc.274.31.21528.CrossRefPubMed

10.

Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, Jiang C, Coppola D, Nicosia SV, Cheng JQ: Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene. 2000, 19: 2324-2330. 10.1038/sj.onc.1203598.CrossRefPubMed

11.

Cheng JQ, Altomare DA, Klein MA, Lee WC, Kruh GD, Lissy NA, Testa JR: Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis. Oncogene. 1997, 14: 2793-2801. 10.1038/sj.onc.1201121.CrossRefPubMed

12.

Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, Testa JR: Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA. 1996, 93: 3636-3641. 10.1073/pnas.93.8.3636.CrossRefPubMedPubMedCentral

13.

Lauffenburger DA, Horwitz AF: Cell migration: a physically integrated molecular process. Cell. 1996, 84: 359-369.CrossRefPubMed

14.

Miranti CK, Brugge JS: Sensing the environment: a historical perspective on integrin signal transduction. Nat Cell Biol. 2002, 4: E83-E90. 10.1038/ncb0402-e83.CrossRefPubMed

15.

Bacus SS, Altomare DA, Lyass L, Chin DM, Farrell MP, Gurova K, Gudkov A, Testa JR: Akt is frequently upregulated in HER-2/ neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene. 2002, 21: 3532-3540. 10.1038/sj.onc.1205438.CrossRefPubMed

16.

Morini M, Mottolese M, Ferrari N, Ghiorzo F, Buglioni S, Mortarini R, Noonan DM, Natali PG, Albini A: The α₃β₁ integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int J Cancer. 2000, 87: 336-342. 10.1002/1097-0215(20000801)87:3<336::AID-IJC5>3.3.CO;2-V.CrossRefPubMed

17.

Masure S, Haefner B, Wesselink J-J, Hoefnagel E, Mortier E, Verhasselt P, Tuytelaars A, Gordon R, Richardson A: Molecular cloning, expression and characterization of the human serine/threonine kinase Akt-3. Eur J Biochem. 1999, 265: 353-360. 10.1046/j.1432-1327.1999.00774.x.CrossRefPubMed

18.

Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV, Cheng JQ: AKT1/PKBα kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol. 2001, 159: 431-437.CrossRefPubMedPubMedCentral

19.

Kim D, Kim S, Koh H, Yoon SO, Chung AS, Cho KS, Chung J: Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J. 2001, 15: 1953-1962. 10.1096/fj.01-0198com.CrossRefPubMed

20.

Park BK, Zeng X, Glazer RI: Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells. Cancer Res. 2001, 61: 7647-7653.PubMed

21.

Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH, Testa JR: Akt activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res. 2001, 61: 589-593.PubMed

22.

Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, Ferrandina G, Benedetti Panici P, Mancuso S, Neri G, Testa JR: Molecular alterations of the AKT2 oncogene in ovarion and breast carcinomas. Int J Cancer. 1995, 64: 280-285.CrossRefPubMed

23.

Czauderna F, Fechtner M, Aygun H, Arnold W, Klippel A, Giese K, Kaufmann J: Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA. Nucleic Acids Res. 2003, 31: 670-682. 10.1093/nar/gkg141.CrossRefPubMedPubMedCentral

Title: Akt2: a role in breast cancer metastasis
Authors: Noan-Minh Chau
Margaret Ashcroft
Publication date: 01-02-2003
Publisher: BioMed Central
Published in: Breast Cancer Research / Issue 1/2003
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr739

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2003

Expression of androgen receptor and prostate-specific antigen in male breast carcinoma

Prevention of mammary carcinogenesis by short-term estrogen and progestin treatments

Radiotherapeutic use of 2-deoxy-2-[18F]fluoro-D-glucose – a comment

Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy

Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?

Breast Cancer Therapy Annual – today's drug treatment of cancer?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer